Mirae Asset Global Investments Co., Ltd. Protagonist Therapeutics, Inc Transaction History
Mirae Asset Global Investments Co., Ltd.
- $22.5 Billion
- Q3 2024
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 2,130 shares of PTGX stock, worth $101,430. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,130
Previous 1,751
21.64%
Holding current value
$101,430
Previous $60,000
58.33%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding PTGX
# of Institutions
212Shares Held
59.1MCall Options Held
19KPut Options Held
107K-
Farallon Capital Management LLC San Francisco, CA5.84MShares$278 Million0.98% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$274 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.29MShares$252 Million3.06% of portfolio
-
Bvf Inc San Francisco, CA3.32MShares$158 Million3.52% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.24MShares$154 Million0.0% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.34B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...